C12N 2501/23
Interleukins [il]
Official title: Interleukins [IL]
C12N2501/23 (Interleukins [il]) appears on 1,915 US grants and 4,157 published applications in this corpus.
Search patents in C12N- Granted patents
- 1,915
- Published applications
- 4,157
- Assignees
- 1,583
- Inventors
- 6,884
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 2 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 4 | 0 |
| 1993 | 7 | 0 |
| 1994 | 8 | 0 |
| 1995 | 16 | 0 |
| 1996 | 8 | 0 |
| 1997 | 26 | 0 |
| 1998 | 37 | 0 |
| 1999 | 28 | 0 |
| 2000 | 31 | 0 |
| 2001 | 30 | 18 |
| 2002 | 22 | 66 |
| 2003 | 31 | 86 |
| 2004 | 22 | 86 |
| 2005 | 23 | 101 |
| 2006 | 31 | 88 |
| 2007 | 17 | 71 |
| 2008 | 28 | 75 |
| 2009 | 35 | 104 |
| 2010 | 53 | 121 |
| 2011 | 37 | 95 |
| 2012 | 56 | 91 |
| 2013 | 44 | 99 |
| 2014 | 65 | 102 |
| 2015 | 79 | 115 |
| 2016 | 75 | 126 |
| 2017 | 81 | 152 |
| 2018 | 78 | 160 |
| 2019 | 89 | 211 |
| 2020 | 98 | 234 |
| 2021 | 127 | 336 |
| 2022 | 100 | 368 |
| 2023 | 103 | 328 |
| 2024 | 154 | 373 |
| 2025 | 150 | 326 |
| 2026 | 118 | 225 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2501/2302Interleukin-2Indexing code563
- C12N 2501/2315Interleukin-15Indexing code324
- C12N 2501/235Leukemia inhibitory factor [lif]Indexing code322
- C12N 2501/2306Interleukin-6Indexing code272
- C12N 2501/2307Interleukin-7Indexing code202
- C12N 2501/2321Interleukin-21Indexing code194
- C12N 2501/2303Interleukin-3Indexing code164
- C12N 2501/2304Interleukin-4Indexing code149
All 36 subgroupsShow fewer
- C12N 2501/2312Interleukin-12Indexing code103
- C12N 2501/2301Interleukin-1Indexing code100
- C12N 2501/2311Interleukin-11Indexing code48
- C12N 2501/231Interleukin-10Indexing code41
- C12N 2501/2318Interleukin-18Indexing code38
- C12N 2501/2309Interleukin-9Indexing code23
- C12N 2501/2308Interleukin-8Indexing code17
- C12N 2501/2313Interleukin-13Indexing code12
- C12N 2501/2323Interleukin-23Indexing code12
- C12N 2501/2305Interleukin-5Indexing code10
- C12N 2501/2334Interleukin-34Indexing code9
- C12N 2501/2333Interleukin-33Indexing code8
- C12N 2501/2327Interleukin-27Indexing code7
- C12N 2501/2317Interleukin-17Indexing code6
- C12N 2501/2322Interleukin-22Indexing code3
- C12N 2501/2325Interleukin-25Indexing code3
- C12N 2501/2316Interleukin-16Indexing code2
- C12N 2501/2331Interleukin-31Indexing code2
- C12N 2501/2314Interleukin-14Indexing code1
- C12N 2501/232Interleukin-20Indexing code1
- C12N 2501/2324Interleukin-24Indexing code1
- C12N 2501/2332Interleukin-32Indexing code1
- C12N 2501/2335Interleukin-35Indexing code1
- C12N 2501/2319Interleukin-19Indexing code0
- C12N 2501/2326Interleukin-26Indexing code0
- C12N 2501/2328Interleukin-28Indexing code0
- C12N 2501/2329Interleukin-29Indexing code0
- C12N 2501/233Interleukin-30Indexing code0
Recent patents
- Methods of culturing quiescent hematopoietic stem cells and treatment methods6 Oct 2026US 12,753,389 B2Icahn School of Medicine at Mount Sinai
- Monoclonal antibody drug sensitivity in multiple myeloma patients6 Oct 2026US 12,754,180 B2The Regents of the University of Colorado, a body corporate
- Haematopoietic stem/progenitor cells29 Sep 2026US 12,747,424 B2Murdoch Childrens Research Institute
- Compositions and methods for providing hematopoietic function without HLA matching22 Sep 2026US 12,741,001 B2Fred Hutchinson Cancer Center
- Fixed ratio ex vivo activated mixed lymphocyte products for use in the treatment of cancer22 Sep 2026US 12,742,153 B2Children's National Medical Center
- Nk cell compositions and preparations for immunotherapy and methods for their production8 Oct 2026US 2026/0308226 A1Deverra Therpaeutics Inc.
- Metabolically enhanced vd1 t cells and uses thereof8 Oct 2026US 2026/0308518 A1
- Compositions comprising and methods of using dendritic cell exosomes8 Oct 2026US 2026/0308524 A1Baylor College of Medicine
- Methods of enhancing or modifying nk cells8 Oct 2026US 2026/0308525 A1Zelluna Immunotherapy AS
- Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy1 Oct 2026US 2026/0293881 A1Iovance Biotherapeutics, Inc.
Most cited
By later US patents
- Human mesenchymal stem cells813US 5,486,359 AOsiris Therapeutics, Inc. · 1996
- Method for treating connective tissue disorders633US 5,226,914 A1993
- Handheld electromechanical surgical system627US 10,932,784 B2Covidien LP · 2021
- Connective tissue regeneration using human mesenchymal stem cell preparations470US 5,811,094 AOsiris Therapeutics, Inc. · 1998
- Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells444US 5,197,985 A1993